Illustrative image of compounded tirzepatide rapid-dissolve tablets offered through NexLife’s sublingual protocol for eligible patients seeking a non-injectable option. A licensed provider determines whether the formulation is clinically appropriate. Compounded tirzepatide RDT is not FDA-approved.
Illustrative image of compounded tirzepatide rapid-dissolve tablets offered through NexLife’s sublingual protocol for eligible patients seeking a non-injectable option. A licensed provider determines whether the formulation is clinically appropriate. Compounded tirzepatide RDT is not FDA-approved.